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Cancers are often affected by derangements in mitochondrial (mt) function, as well as mtDNA mutations. In
this issue, Tan et al. (2015) demonstrate that onlymtDNA-depleted cancer cells capable of recoveringmtDNA
from the host formmetastasizing cancers in vivo, revealing an essential requirement for oxidative phosphor-
ylation in tumor progression.For close to one century, it has been
known that cancer cells tend to assimilate
glucose and other building blocks for
anabolic reactions at a higher pace than
their normal counterparts and that this pe-
culiarity is coupled to comparatively low
levels of oxidative phosphorylation (Gal-
luzzi et al., 2013). One explanation that
has advanced for this so-called ‘‘Warburg
phenomenon’’ is a mitochondrial defect
that would be explained by mutations in
mitochondrial DNA (mtDNA), reductions
in mtDNA copy numbers, and/or reduced
transcription and translation of nuclear
genes coding for mitochondrial proteins
(Brandon et al., 2006, Wallace 2012).
While it is as yet impossible to engineer
stable cell lines that lack mitochondria, it
is feasible to culture cells in conditions
that preclude the replication of mtDNA in
specific auxotrophic media (that contain
extra pyruvate, as well as uridine), thus re-
sulting in the generation of mtDNA null (or
so-called r) cells, in which four out of the
five respiratory chain complexes lack
mtDNA-encoded subunits. r cells exhibit
a complete deficiency in oxidative phos-
phorylation and hence contain mitochon-
dria that consume rather than generate
ATP to maintain their essential metabolic
functions (Wallace 2012).
Tan et al. (2015) now show that twomu-
rine cancer cell lines (B16 melanoma and
4T1 breast carcinoma), which had been
rendered r in vitro, formed tumors in vivo
with a latency of several weeks compared
to their mtDNA-sufficient (r+) parental
controls. Once these delayed tumors
emerged, they progressed as rapidly as
r+ controls. The authors recovered thein vivo derivatives of the originally r cells
at different stages of malignant progres-
sion by isolating primary tumors from the
subcutaneous inoculation site, circulating
tumor cells, as well as lung metastases. In
contrast to r cells cultured in vitro, their
in vivo products rapidly formed tumors
upon re-injection into mice. Moreover,
the in vivo derivatives of r cells exhibited
a tumor progression-related recovery
in mitochondrial biochemistry, ultrastruc-
ture, and function. Hence, developing
and progressing tumors were character-
ized by the reformation of respiratory
chain supercomplexes, the reacquisition
of normal mitochondrial morphology
with cristae, as well as the restoration of
oxidative phosphorylation. This gradual
recovery was correlated with a relative
increase in the abundance of mtDNA,
which augmented with each step of tumor
progression, reaching close-to-normal
levels as the tumor cells attained the
blood stream for metastatic dissemina-
tion (Figure 1A). This mtDNA was tran-
scribed in a normal fashion, hence fully
contributing to mitochondrial biogenesis
in formerly r cells. Taking advantage of
polymorphisms in the mtDNA sequence
between different mouse strains and cell
lines, Tan et al. (2015) discovered that
the mtDNA contained in these progress-
ing cancers was not amplified from resid-
ual mtDNA that might have contaminated
the original cancer cell line, but rather was
acquired from the host. Hence, r cells
somehow recover mtDNA from the host,
which restores their metabolic capacities
to a level compatible with tumor
progression.Cell MetabolismHow can mtDNA be transferred from
one cell to another? Although it is techni-
cally feasible to transfect mtDNA isolated
from one cell line into another one, this
procedure generally does not cause the
mtDNA to be introduced into the mito-
chondrial matrix and hence fails to restore
normal mitochondrial biogenesis. To
functionally transmit mtDNA, it is neces-
sary to transfer entire mtDNA-containing
mitochondria from r+ cells to r cells.
Although this can be achieved in vitro by
microinjecting isolated r+ organelles into
r cells, the standard procedure to trans-
fer mtDNA from one cell to the other is
more sophisticated. Usually, the mtDNA-
containing cell is enucleated (meaning
that its only DNA is mitochondrial) and
then fused with the r cell (whose only
DNA is nuclear) resulting in a cytoplasmic
hybrid (or ‘‘cybrid’’) that re-unites mtDNA
from one cell and nuclear DNA from
another cell (Schon et al., 2012).
How, then, is mtDNA from the host
transferred into the initially r cancer
cell? Given the aforementioned experi-
ence in laboratory technology, it appears
improbable that r cells subjected to
Darwinian selection in vivo would have
developed a strategy to selectively take
upmtDNA from the host (Figure 1B). It ap-
pears far more plausible that they incor-
porate entire host mitochondria (Rogers
and Bhattacharya, 2013). How could this
be achieved? Tumor cells might acquire
host cell organelles by phagocytosis,
although the engulfed cargo would then
usually be targeted for lysosomal destruc-
tion, unless the host mitochondrion man-
ages to escape the phagocytic vesicle21, January 6, 2014 ª2015 Elsevier Inc. 11
Figure 1. Cancer Progression of Initially mtDNA-Deficient Cells
(A) Consequences of mtDNA recovery on the properties of tumors generated from originally mtDNA-
deficient (r cells).
(B–D) Potential mechanisms of host mtDNA uptake by r cells. r cells might incorporate ‘‘naked’’ DNA
from the host (B), phagocytose portions of host cells that comprise mtDNA-containing mitochondria
(C), or fuse with host cells (D). In this latter scenario, the originally r cell would not recover only mtDNA,
but would also recover chromosomes from the nuclear host genome.
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might occur at a low frequency, explaining
why r cancers become palpable approx-
imately 20 days later than their mtDNA-
sufficient counterparts (Tan et al., 2015).
Alternatively, tumor cells might fuse with
host cells (Figure 1D). Such somatic cell-
cell fusion events have been documented
in oncogenesis (Vitale et al., 2011). How-
ever, at difference with the cybrid technol-
ogy described above, host cells, which
usually are nucleated, would be expected
to contribute both their mtDNA and nu-
clear DNA to the resulting somatic hybrid
cells. Cell fusion among somatic cells is
well documented to result in a non-physi-
ological increase in ploidy (with conse-
quent DNA damage responses and
endoplasmic reticulum stress), usually re-
sulting in apoptotic suicide, senescence,12 Cell Metabolism 21, January 6, 2014 ª201or immune system-mediated elimination
of the hyperploid product (Senovilla
et al., 2012). However, at least occasion-
ally such hyperploid cells may succeed
in reducing their ploidy, hence generating
highly tumorigenic cells containing a
close-to-normal number of chromosomes
(Vitale et al., 2011).
In order to discriminate between these
potential scenarios, it will be important
to analyze the cancers generated from
originally r cells for changes in their
ploidy, as well as for the relative contribu-
tion of nuclear DNA from tumor and host
cells. The polyploidization-depolyploid-
ization cycle that frequently accompanies
malignant progression (Vitale et al., 2011)
could have caused mixing of the nuclear
genomes from tumor and host cells
accompanied by recovery of mtDNA. Irre-5 Elsevier Inc.spective of this incognita, the results by
Tan et al. (2015) underscore the probable
importance of mtDNA-dependent mito-
chondria biogenesis for oncogenesis
and tumor progression. If mitochondrial
respiration were absolutely required for
the fitness of cancer stem cells, it would
be possible to gauge tumor progression
by administering pharmacological inhibi-
tors of respiratory chain complexes, as
this has been exemplified for KRAS-
induced cancers (Shackelford et al.,
2013; Viale et al., 2014). The report by
Tan et al. now suggests that mtDNA-
dependent metabolic processes, most
likely oxidative phosphorylation, can be
therapeutically targeted in a vast spec-
trum of different cancers. Irrespective of
this speculation, the paper by Tan et al.
highlights the malicious capacity of tumor
cells to acquire mtDNA from benign
bystander cells.REFERENCES
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